Chemoembolization with or without an oral treatment drug (Sorafenib) for liver cancer that cannot be removed surgically.
Participants can have Cirrhosis and at least 1 lesion greater than 2 centimeters or an AFP greater than 400 and at least 1 lesion greater than 2 centimeters. Disease must be limited to the liver but must be less than 50% diseased. RFA is allowed if it was more than 4 weeks ago. Participants also include those who have Child-Pugh A or B7.
Exclusions include, but are not limited to: Detectable ascites on physical exam or main portal vein invasion.
“I have an aggressive type of cancer and it was time to take drastic measures…When I heard about the trial from Dr. Hodge, I felt privileged to have this type of care and the chance to help others who may be in my shoes one day.”